Pronóstico del mercado terapéutico de enfermedades infecciosas de América del Sur y Central hasta 2030 – Análisis regional – por clase de medicamento (antivirales, antibacterianos, antifúngicos y otros), indicación (VIH, hepatitis, tuberculosis, influenza, VPH y otros) , vía de administración (oral, parenteral, tópica y otras) y canal de distribución (farmacias hospitalarias, farmacias minoristas y otras)
Las crecientes oportunidades en los países en desarrollo impulsan el mercado de terapias para enfermedades infecciosas de América del Sur y Central
Se prevé que la creciente incidencia de enfermedades infecciosas aumentará aumentar las ventas de medicamentos terapéuticos para enfermedades infecciosas en los países en desarrollo. Además, las altas inversiones en investigación sanitaria y ciencias biológicas en los países emergentes desempeñan un papel clave en la promoción de las últimas tecnologías en los países en desarrollo, lo que, a su vez, respalda la inclinación hacia el diagnóstico y tratamiento de enfermedades infecciosas. Por ejemplo, ONUSIDA pide una inversión de 29 mil millones de dólares de aquí a 2025 para satisfacer las necesidades de los países de ingresos bajos y medios en la respuesta al sida. Por lo tanto, se espera que los fabricantes cruciales de productos terapéuticos para enfermedades infecciosas en los mercados emergentes de terapias para enfermedades infecciosas en Brasil sean testigos de oportunidades lucrativas en el futuro. Esto se debe a la alta prevalencia de enfermedades infecciosas como la hepatitis, las HAI, el VIH y la influenza; una gran población de pacientes; un aumento de la renta disponible de la población; mejorar la infraestructura de la atención sanitaria; y el creciente turismo médico en estos países.
Descripción general del mercado de terapias para enfermedades infecciosas de América del Sur y Central
El mercado de terapias para enfermedades infecciosas de América del Sur y Central está subsegmentado en Brasil, Argentina y el resto de América del Sur y Central. Se espera que el mercado terapéutico de enfermedades infecciosas en América del Sur y Central crezca debido a la mayor prevalencia de enfermedades infecciosas, el aumento de las actividades de investigación y el aumento del gasto sanitario por parte de los países de la región. Brasil ha logrado enormes avances en el sector de la salud debido a la expansión del gasto en atención médica. Según la Administración de Comercio Internacional, Brasil gasta ~9,1% de su PIB en atención médica y es el principal mercado de atención médica en América Latina. Se estima que el mercado de terapias para enfermedades infecciosas en Brasil experimentará un auge debido a la creciente prevalencia de enfermedades infecciosas.
Las enfermedades infecciosas siguen siendo causas importantes de muerte en Brasil. Una encuesta reveló que se observaba una elevada carga de enfermedades infecciosas entre hombres y niños menores de 5 años, principalmente debido al VIH/SIDA. Según datos proporcionados por el Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA (ONUSIDA), en 2022, alrededor de 990.000 personas vivían con VIH y SIDA en Brasil. Por lo tanto, debido a los factores antes mencionados, se prevé que el mercado terapéutico de enfermedades infecciosas en Brasil crezca durante el período de pronóstico.
Ingresos y pronóstico del mercado de terapias para enfermedades infecciosas de América del Sur y Central hasta 2030 (millones de dólares estadounidenses)
Segmentación del mercado de terapias para enfermedades infecciosas de América del Sur y Central
América del Sur y Central El mercado de terapias para enfermedades infecciosas se clasifica en clase de fármaco, indicación, vía de administración, canal de distribución y país.
Según la clase de fármaco, el mercado terapéutico de enfermedades infecciosas de América del Sur y Central se segmenta en antivirales, antibacterianos, antifúngicos y otros. El segmento antiviral tuvo la mayor participación de mercado en 2022.
En términos de indicación, el mercado terapéutico de enfermedades infecciosas de América del Sur y Central está segmentado en VIH, hepatitis, tuberculosis, influenza, VPH y otros. El VIH tuvo la mayor participación de mercado en 2022.
Según la vía de administración, el mercado terapéutico de enfermedades infecciosas de América del Sur y Central se segmenta en oral, parenteral, tópico y otros. El segmento oral tuvo la mayor participación de mercado en 2022.
En términos de canal de distribución, el mercado terapéutico de enfermedades infecciosas de América del Sur y Central está segmentado en farmacias hospitalarias, farmacias minoristas y otros. Las farmacias hospitalarias tuvieron la mayor participación de mercado en 2022.
Por país, el mercado terapéutico de enfermedades infecciosas de América del Sur y Central está segmentado en Brasil, Argentina y el resto de América del Sur y Central. Brasil dominó la cuota de mercado de terapias para enfermedades infecciosas en América del Sur y Central en 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc y Pfizer Inc son algunas de las empresas líderes que operan en el mercado terapéutico de enfermedades infecciosas de América del Sur y Central.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - South & Central America Market Analysis
5.1 South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. South & Central America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Infectious Disease Therapeutics Market - Country Analysis
10.1 South & Central America Infectious Disease Therapeutics Market
10.1.1 South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Brazil: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.2.2 Brazil: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.2.3 Brazil: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.2.4 Brazil: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.3 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.4 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Argentina: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.4.2 Argentina: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.4.3 Argentina: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.4.4 Argentina: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.5 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.6 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.6.2 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.6.3 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.6.4 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. South & Central America Infectious Disease Therapeutics Market Segmentation
Table 2. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 7. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 20. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. South & Central America Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. South & Central America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. South & Central America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. South & Central America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. South & Central America Infectious Disease Therapeutics Market, By Key Country - Revenue (2022) (US$ Million)
Figure 26. South & Central America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.